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declined effectively without significant differences between 2 groups
(Dsystolic/diastolic BP: pre-MPW; 25.7 17.7/14.2 11.3 vs.
post-MPW; 25.7 16.3/13.1 10.9 mm Hg). Home morning and
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Abstract: Angiotensin receptor blockers may be an appropriate first-
line agent for postmenopausal women with hypertension because the
activation of renin–angiotensin–aldosterone system is suggested as
one possible mechanism of postmenopausal hypertension. However,
there are few studies substantiating this effect. This study aimed to
investigate clinic and home blood pressure (BP) lowering effect of
fimasartan, a new angiotensin receptor blocker, in postmenopausal
women with hypertension.
Among patients with hypertension enrolled in K-Mets Study, 1373
women with fimasartan as a first antihypertensive drug and 3-months
follow-up data were selected. They were divided into 2 groups; pre-
menopausal women (pre-MPW; n¼ 382, 45.3 4.6 years) and post-
menopausal women (post-MPW; n¼ 991, 60.9 8.2 years).
Baseline clinic systolic BP was not different (pre-MPW;
152.9 15.2 vs. post-MPW; 152.8 13.5 mm Hg), but diastolic BP
was lower in post-MPW (pre-MPW; 95.7 9.4 vs. post-MPW;
91.9 9.4 mm Hg, P<0.001). After 3-month treatment, clinic BPng-Soo Kim, MD, ee, MD,
d Jeong Bae Park, MD
evening systolic BP decreased similarly in both groups (Dmorning/
evening systolic BP: pre-MPW; 21.3 17.9/23.1 15.8 vs. post-
MPW; 20.4 17.3/20.2 19.2 mm Hg). Fimasartan also signifi-
cantly decreased the standard deviations of home morning and evening
systolic BP of pre-MPW and post-MPW.
Fimasartan was a similarly effective BP lowering agent in both post-
MPW and pre-MPW with hypertension, and it also decreased day-to-
day BP variability.
(Medicine 95(22):e3764)
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor,
ARB = angiotensin receptor blocker, BPV = blood pressure
variability, CV = cardiovascular, MPW = menopausal women, SD
= standard deviation.
INTRODUCTION
A ging is an important determinant of hypertension,
1–5 but
the age-related increase of systolic blood pressure (BP) is
more rapid in women than in men after the mid-forties.1,5 The
prevalence of hypertension in premenopausal women is much
lower than that in men of similar age, but it increased abruptly
after menopause.1,4–11 Other cardiovascular (CV) risk factors
such as dyslipidemia, diabetes mellitus, or obesity also become
to be more common in postmenopausal than in premenopausal
women.4,5,11,12 Strict BP control with antihypertensive drug
as well as lifestyle modification is recommended to minimize
CV morbidity and mortality of postmenopausal women with
hypertension.12
The renin–angiotensin–aldosterone system is a major
body system for controlling BP and its blockers have been
widely used in patients with hypertension to lower high BP.13,14
The renin–angiotensin–aldosterone system has been suggested
to play an important role in postmenopausal hypertension
because of its activation after menopause.15–17 Angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin receptor
blockers (ARBs) may be appropriate as a first-line agent for
postmenopausal hypertension,12 and small studies showed
the good antihypertensive effect of ACEIs or ARBs in post-
menopausal women with hypertension.18,19 However, their
BP-lowering effect in a large population of postmenopausal
women with hypertension has rarely been determined, especi-
ally using measurements of home BP.
Home BP measurements by appropriately trained patients
may be more reliable and reproducible than traditional clinic BP
data, and it has been demonstrated that home BP was superior toto ambulatory BP for predicting CV
ines for the management of hypertension
P measurements to accurately diagnose
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11.5 12.4 mm Hg, respectively) of pre-MPW (Figure 1).
Daily dosage of fimasartan was 30mg (47 pre-MPW and 105
post-MPW), 60mg (287 pre-MPW and 771 post-MPW), or







Age, y 45.3 4.6 60.9 8.2 <0.001
Height, cm 158.7 4.8 155.8 5.5 <0.001
Weight, kg 63.2 9.6 60.6 8.6 <0.001
BMI, kg/m2 25.1 3.5 24.9 3.3 0.40
BMI >25, kg/m2 176 (46) 452 (46) 0.67
Waist, cm 82.1 8.8 82.9 8.8 0.14
Waist >80 cm 204 (53) 571 (58) 0.33
Current smoker 19 (5) 23 (2) 0.037
Diabetes mellitus 43 (11) 181 (18) <0.001
Dyslipidemia 189 (49) 526 (53) 0.002
Metabolic syndrome

199 (52) 505 (51) 0.76hypertension and assess the response to antihypertensive
agents.20,21 Home BP measurements also provide day-to-day
BP variability (BPV), which has been shown to be associated
with stroke mortality,22 CV events,23 or hypertensive target
organ damage.24,25
Fimasartan, a new ARB, has been demonstrated to effec-
tively and safely control hypertension in the Safe-KanArb
study.26 The objective of the present study was to investigate
antihypertensive effect of fimasartan in the clinic and at
home after 3-month treatment in postmenopausal women with
low-to-moderate risk hypertension.
METHODS
This investigation is a substudy of K-Mets Study, which is
a prospective, multicenter, single-arm, observational study. The
study design, demographic characteristics, baseline BP data,
and metabolic risk factors have been already described.27 This
study was approved by the institutional review board of Cheil
General Hospital on behalf of 582 primary care clinics. Another
10 university hospitals approved this study through their
own institutional review board. All study subjects signed the
informed consents.
Study Population
Between October 17, 2011 and October 31, 2012, total
10,601 hypertensive patients were enrolled from 582 primary
care clinics and 11 university hospitals in South Korea. Patients
with hypertension at least 20 years of age who intended to use
fimasartan, and agreed to participate in the study and to be in
fasting state at each visit, were included. Patients who were
treated with fimasartan at baseline and premenopausal women
not practicing an effective method of birth control before entry
and throughout the study were excluded. Among enrolled
patients, 1373 women who answered a baseline menopausal
question, who were not taking estrogen, and who completed 3-
month treatment with fimasartan as a first antihypertensive drug
and follow-up visit were included in this study. Daily dosage of
fimasartan 30, 60, or 120mg was prescribed at the discretion of
the attending physician. Postmenopausal women (post-MPW)
were identified if their final menstrual period had occurred more
than 1 year before the interview. Others were considered as
premenopausal women (pre-MPW).
Measurements of BP
The Omron HEM-7220 and the Omron HEM-7200 (both
Omron, Tokyo, Japan) were used to measure BP in the clinic and
at home, respectively. They were automated upper-arm cuff
devices based on the cuff oscillometric principle. Clinic BP was
measured under standardized conditions (in the same arm by the
same physician or nurse). The study participants were educated
about self-measurement of their own blood pressure at home.
They were instructed to take their blood pressure twice in the
morning and evening. An average of 2 or more BP readings at
2-minute intervals on each occasion from the same arm was
recorded for 7 consecutive days. Morning BP was measured
within 1 hour of awakening, after urination, in the sitting
position, after resting for 5 minutes, and before taking medi-
cations or eating. In the evening, BP was measured before going
to bed, after resting for 5 minutes, and in the sitting position. An
average of 6 days’ recordings from the second to the seventh day
Kim et alwas used for the analysis.27 Baseline assessment including
health questionnaire and BP measurements were conducted
before and after the 3-month treatment with fimasartan. Home
2 | www.md-journal.comBPV, which represents day-by-day BPV, was defined as the
standard deviation (SD) of home BP.
Statistical Analysis
The baseline characteristics of the study subjects were
compared between pre-MPW and post-MPW using the x2 test
for dichotomous variables or Student t test for continuous vari-
ables. Changes of clinic and home BP and SD of home BP
between baseline and at 3-months follow-up visit were examined
using the paired t test. Differences of decline of BPs and SDs
between 2 groups after 3 months were compared using Student t
test. Values were considered to be statistically significant, when
P<0.05. All statistical analyses were performed using SPSS for
window version 12 (SPSS Inc, Chicago, IL).
RESULTS
Baseline Characteristics
In this study group, 2.5 times more women were in
postmenopausal state. They were older (60.9 8.2 vs.
45.3 4.6 years of pre-MPW, P<0.001), had lower height
and body weight, but had similar body mass index and waist
circumference (Table 1). Post-PMW had more diabetes mellitus
and dyslipidemia. About a half of patients in both groups had
metabolic syndrome by Adult Treatment Panel criteria.
Effects of Fimasartan on Clinic BP
Baseline clinic systolic BP was not different between 2
groups (pre-MPW; 152.9 15.2 vs. post-MPW; 152.8 13.5
mm Hg, P¼0.89), but diastolic BP was lower (pre-MPW;
95.7 9.4 vs. post-MPW; 91.9 9.4 mm Hg, P<0.001) and
pulse pressure was higher in post-MPW (pre-MPW; 57.2 12.6
vs. post-MPW; 60.9 12.0 mm Hg, P<0.001) (Table 2).
Fimasartan lowered either clinic systolic or diastolic BP effec-
tively in both groups after 3 months. Mean change of clinic
systolic BP (25.7 16.3 mm Hg), diastolic BP (13.1 10.9
mmHg), or pulse pressure (12.7 12.7 mmHg) of post-MPW
was similar to those (25.7 17.7, 14.2 11.3, and
Medicine  Volume 95, Number 22, June 2016Data are expressed as number (%) or mean standard deviation.
BMI¼ body mass index.
Metabolic syndrome by Adult Treatment Panel (ATP) criteria.
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TABLE 2. Changes of Clinic Blood Pressure (BP) After 3-Month Treatment With Fimasartan
Premenopause (N¼ 382) Postmenopause (N¼ 991)
Baseline After 3 Months Baseline After 3 Months
Systolic BP, mm Hg 152.9 15.2 127.2 13.1 152.8 13.5 127.1 12.5
D systolic BP 25.7 17.7 25.7 16.3
Diastolic BP, mm Hg 95.7 9.4 81.5 9.5 91.9 9.4y 78.9 8.8,y
D diastolic BP 14.2 11.3 13.1 10.9
Pulse pressure, mm Hg 57.2 12.6 45.7 9.1 60.9 12.0y 48.2 9.9,y
D pulse pressure 11.5 12.4 12.7 12.7
Heart rate (/min) 75.8 9.4 74.3 9.6 73.5 9.9y 71.1 8.3,y
D heart rate 1.5 9.5 2.4 9.5
Data are expressed as mean standard deviation.
P<0.005 versus baseline.
y
Medicine  Volume 95, Number 22, June 2016 ARB in Postmenopausal Hypertension120mg (48 pre-MPW and 115 post-MPW). All dosages
decreased clinic systolic and diastolic BP without difference
between 2 groups after 3 months (Figure 2).
Effects of Fimasartan on Home BP
Baseline morning and evening systolic BP were not differ-
ent, but diastolic BP was lower and pulse pressure was higher in
post-MPW (Table 3). Fimasartan decreased all home systolic
BP, diastolic BP, and pulse pressure in both groups effectively
after 3 months. Mean change of morning systolic BP
(20.4 17.3 mm Hg) or evening systolic BP (20.2 19.2
mm Hg) of post-MPW was not different from those
(21.3 17.9 and 23.1 15.8 mm Hg, respectively) of
pre-MPW. Morning systolic BP at 3-month was higher in
post-MPW (pre-MPW; 123.1 14.0 mm Hg vs. post-MPW;
P<0.01 versus premenopause.127.0 18.4 mm Hg, P¼ 0.031). Pre-MPW showed more
decreased morning diastolic BP (pre-MPW; 13.3 12.0
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 Pre-MPW     Post-MPW 
FIGURE 1. Effects of fimasartan on clinic blood pressure (BP).
Fimasartan lowered clinic systolic BP (SBP), diastolic BP (DBP), and
pulse pressure (PP) effectively without difference between pre-
menopausal (pre-MPW) and postmenopausal women (post-
MPW) with hypertension after 3-month treatment. Values are
mean standard error.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.and evening diastolic BP (pre-MPW; 13.8 10.3 vs. post-
MPW; 9.7 10.9, P¼ 0.001) (Figure 3). Baseline morning
and evening heart rate were greater in pre-MPW, but, after 3
months, they became similar to those of post-MPW (Table 3).
Fimasartan decreased the day-to-day BPV after 3-month
treatment. It lowered SDs of morning systolic BP in post-MPW
(from 9.26 7.31 to 7.63 5.48 mm Hg, P¼ 0.001) and pre-
MPW (from 8.96 7.74 to 6.76 5.03mmHg,P¼ 0.006). SDs
of evening systolic BP of post-MPW (from 9.03 5.44 to
7.83 5.24 mm Hg, P¼ 0.002) and pre-MPW (from
9.66 8.18 to 7.31 5.69 mm Hg, P¼ 0.002) were also
decreased after 3 months. Mean changes of SDs of morning
and evening systolic BP were not significantly different
between 2 groups (Table 4). SD of heart rate was not changed
after 3-month treatment.Adverse Events
Adverse events were reported in 13 (3.4%) of pre-MPW
and 13 (1.3%) of post-MPW (P¼ 0.015). All adverse events
mmHg 
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FIGURE 2. Changes of clinic blood pressure (BP) according to
daily dosages of fimasartan 30, 60, or 120mg. All dosages
decreased clinic systolic BP (SBP) and diastolic BP (DBP) without
difference between premenopausal (pre-MPW) and postmeno-
pausal women (post-MPW) with hypertension after 3-month
treatment. Values are mean standard error.
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TABLE 3. Changes of Home Blood Pressure (BP) After 3-Month Treatment With Fimasartan
Premenopause Postmenopause
Baseline After 3 Months Baseline After 3 Months
Morning N¼ 128 N¼ 297
Systolic BP, mm Hg 144.4 19.6 123.1 14.0 147.4 21.0 127.0 18.4,y
D systolic BP 21.3 17.9 20.4 17.3
Diastolic BP, mm Hg 89.8 13.1 76.6 9.3 85.5 13.2y 75.5 12.0
D diastolic BP 13.3 12.0 10.0 10.6y
Pulse pressure, mm Hg 54.5 11.0 46.5 8.6 61.9 13.7y 51.5 11.7,y
D pulse pressure 8.1 9.4 10.4 10.3y
Heart rate (/min) 75.8 12.3 72.7 10.4 71.0 10.6y 70.8 10.2
D heart rate 2.8 8.4 0.2 8.0y
Evening N¼ 120 N¼ 269
Systolic BP, mm Hg 147.3 18.7 124.1 13.5 146.4 21.2 126.1 19.5
D systolic BP 23.1 15.8 20.2 19.2
Diastolic BP, mm Hg 90.4 11.7 76.6 8.9 84.1 13.0y 74.5 12.8
D diastolic BP 13.8 10.3 9.7 10.9y
Pulse pressure, mm Hg 56.9 11.7 47.6 8.7 62.3 13.7y 51.7 11.2,y
D pulse pressure 13.8 10.3 9.7 10.9
Heart rate (/min) 75.5 10.8 73.4 9.7 72.8 10.5y 72.8 10.8
D heart rate 1.6 8.7 0.0 8.7
Data are expressed as mean standard deviation.
P<0.001 versus baseline.
y
Kim et al Medicine  Volume 95, Number 22, June 2016were minor ones such dizziness or headache except 1 case of
abnormal elevation of hepatic aminotransferases in post-MPW
at 3-month laboratory test. She was asymptomatic and her liver
P<0.01 versus premenopause.function had recovered soon after discontinuing fimasartan
medication. No myocardial infarction, stroke, or death was
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P = .005 
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FIGURE 3. Effects of fimasartan on home blood pressure (BP).
Fimasartan decreased all home morning and evening systolic BP
(SBP) and diastolic BP (DBP) effectively without difference between
premenopausal (pre-MPW) and postmenopausal women (post-
MPW) with hypertension after 3-month treatment. Pre-MPW
showedmoredecreasedmorningdiastolic (P¼0.005) andevening
diastolic BP (P¼0.001). Values are mean standard error.
4 | www.md-journal.comDISCUSSION
This study showed that fimasartan lowered both clinic and
home BP effectively in post-MPW as well as in pre-MPW with
hypertension, and it also decreased day-to-day BPV.
Antihypertensive regimens based on ACEIs, ARBs,
calcium antagonists, diuretics, or beta-blockers lowered BP
effectively and provided protection against major CV events
without difference in both genders.28 However, the National
Health and Nutrition Examination Survey in US showed that
more diuretics were prescribed in hypertensive women (32%)
than in men (22%).29 Also in post-MPW with treated hyperten-
sion, diuretics were the most frequently used antihypertensive
drug.30 Considering post-MPW are more salt sensitive than pre-
MPW,31 diuretics may be a reasonable antihypertensive mono-
therapy. But they have several metabolic complications, and
may not be an adequate choice in post-MPW with metabolic
syndrome that was found in a half of post-MPW in this study.
ACEIs or ARBs may be an appropriate option in this situation.
In post-MPW with hypertension, an ACEI lowered diastolic BP
effectively with the same amount that a diuretic did, but a
diuretic had more metabolic side-effects.18 An ACEI showed
the same BP reduction as a calcium channel blocker in post-
menopausal hypertensive women.32 One observational cohort
study of older women aged 50 to 79 years with hypertension
revealed that monotherapy with calcium channel blockers was
associated with 55% greater risk of CV death compared with
diuretics.33 ACEIs had a similar CV death to diuretics, but it has
been reported that women had 3 times more chance of ACEI-
induced cough than men.34BP-lowering effect of ARBs in post-MPW has been
investigated only in a small number of patients. In a study
of 51 postmenopausal women with hypertension, irbesartan
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Changes of Day-to-Day Blood Pressure (BP) and Heart Rate Variability After 3-Month Treatment With Fimasartan
Premenopause Postmenopause
Baseline After 3 Months Baseline After 3 Months
Morning N¼ 128 N¼ 297
SD of systolic BP, mm Hg 8.96 7.74 6.76 5.03 9.26 7.31 7.63 5.48
D SD of systolic BP 2.20 8.93 1.63 8.46
SD of diastolic BP, mm Hg 5.81 4.97 4.89 3.03 5.64 4.36 4.90 3.33
D SD of diastolic BP 0.91 5.44 0.74 4.92
SD of heart rate (/min) 5.41 4.08 4.85 3.07 5.05 3.61 4.85 3.41
D SD of heart rate 0.63 4.76 0.19 4.73
Evening N¼ 120 N¼ 269
SD of systolic BP, mm Hg 9.66 8.18 7.31 5.69 9.03 5.44 7.83 5.24
D SD of systolic BP 2.35 8.25 1.20 6.25
SD of diastolic BP, mm Hg 6.25 4.93 5.33 3.48 5.41 3.10 5.17 3.11
D SD of diastolic BP 0.92 5.01 0.23 3.95
SD of heart rate (/min) 5.94 4.30 5.54 4.90 5.43 3.50 5.08 3.22
D SD of heart rate 0.47 5.46 0.36 4.10
Data are expressed as mean standard deviation (SD).
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potentiated by coadministration of estradiol.35 Both valsartan
and amlodipine lowered peripheral BP and aortic pulse wave
velocity without differences in a study of 125 postmenopausal
women with hypertension.19
In this study of 991 post-MPW with hypertension, fima-
sartan effectively lowered both clinic systolic and diastolic BP
after 3-month treatment, and mean changes of clinic systolic BP,
diastolic BP, or pulse pressure of post-MPWwere similar to those
of 382 pre-MPW. There were also no differences between 2
groups according to daily dosage of fimasartan 30, 60, or 120mg.
Mean changes of clinic systolic/diastolic BP (25.7 16.3/
13.1 10.9 mm Hg) of post-MPW were similar to those
(26.4 17.3/13.9 11.6mmHg) reported in the naive group
ofSafe-KanArb study.26Fimasartan alsodecreased homesystolic
BP, diastolic BP, and pulse pressure in post-MPW effectively
after 3 months, and mean change of morning or evening systolic
BP of post-MPW was not different from that of pre-MPW.
Because baseline home diastolic BPs were higher in pre-
MPW, their mean changes were greater in pre-MPW.
Old age and female sex have been known to be associated
with increased home BPV.36 In this study, there were no
significant differences of baseline morning and evening home
BPV between pre-MPW and post-MPW despite post-MPW
were older. Although 1 cross-sectional study in Japan showed
that being medicated with ARBs was related to increased home
systolic BPV in patients with antihypertensive treatment for less
than 12 months,37 fimasartan decreased morning and evening
home BPV significantly in both groups after 3 months.
Only minority of post-MPW (1.3%) complained of mild
adverse events, which was less common than those of pre-MPW
(3.4%). This adverse event rate was similar to 3.3% reported in
Safe-KanArb study.26
This study has some limitations. First, menopausal status

P<0.05 versus baseline.was only identified by the questionnaire, not by serum follicle-
stimulating hormone level. However, several clinical and
epidemiologic studies have used self-reported menstrual
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.characteristics to define menopausal status.19,38,39 Second,
post-MPW were older. Because age was not adjusted in stat-
istical analysis, a few differences of baseline characteristics
between pre- and post-MPW may be influenced by aging, but
baseline clinic and home systolic BP was comparable between 2
groups. Third, a control group for the comparison with other
ARBs or other classes of antihypertensive was not included.
However, fimasartan lowered clinic and home BP at least as
effectively as other kinds of antihypertensives in post-MPW
with hypertension. Fourth, only 3-month BP-lowering effects of
fimasartan were observed in this study. Longer-term antihy-
pertensive difference of fimasartan between pre- and post-
MPW may need to be investigated.
In conclusions, fimasartan was a similarly effective BP-
lowering agent in both post-MPW and pre-MPW with hyper-
tension, and it also decreased day-to-day BP variability.
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